Simplified hierarchical linear models for the evaluation of surrogate endpoints

The linear mixed-effects model (Verbeke and Molenberghs, 2000) has become a standard tool for the analysis of continuous hierarchical data such as, for example, repeated measures or data from meta-analyses. However, in certain situations the model does pose insurmountable computational problems. Precisely this has been the experience of Buyse et al. (2000a) who proposed an estimation- and prediction-based approach for evaluating surrogate endpoints. Their approach requires fitting linear mixed models to data from several clinical trials. In doing so, these authors built on the earlier, single-trial based, work by Prentice (1989), Freedman et al. (1992), and Buyse and Molenberghs (1998). While Buyse et al. (2000a) claim their approach has a number of advantages over the classical single-trial methods, a solution needs to be found for the computational complexity of the corresponding linear mixed model. In this paper, we propose and study a number of possible simplifications. This is done by means of a simulation study and by applying the various strategies to data from three clinical studies: Pharmacological Therapy for Macular Degeneration Study Group (1977), Ovarian Cancer Meta-analysis Project (1991) and Corfu-A Study Group (1995).

[1]  R J Carroll,et al.  On meta-analytic assessment of surrogate outcomes. , 2000, Biostatistics.

[2]  E. L. Lehmann,et al.  Theory of point estimation , 1950 .

[3]  G. Molenberghs,et al.  The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.

[4]  Theo Stijnen,et al.  Advanced methods in meta‐analysis: multivariate approach and meta‐regression , 2002, Statistics in medicine.

[5]  Risto Lethonen Multilevel Statistical Models (3rd ed.) , 2005 .

[6]  Geert Molenberghs,et al.  INVESTIGATING THE CRITERION VALIDITY OF PSYCHIATRIC SYMPTOM SCALES USING SURROGATE MARKER VALIDATION METHODOLOGY , 2002, Journal of biopharmaceutical statistics.

[7]  Geert Molenberghs,et al.  The validation of surrogate end points by using data from randomized clinical trials: a case‐study in advanced colorectal cancer , 2004 .

[8]  C. Chuang-Stein,et al.  Surrogate Endpoints in AIDS Drug Development: Current Status , 1998 .

[9]  J. C. van Houwelingen,et al.  Logistic Regression for Correlated Binary Data , 1994 .

[10]  B. Graubard,et al.  Statistical validation of intermediate endpoints for chronic diseases. , 1992, Statistics in medicine.

[11]  Charles E. Heckler,et al.  Applied Multivariate Statistical Analysis , 2005, Technometrics.

[12]  T. Fleming,et al.  Perspective: validating surrogate markers--are we being naive? , 1997, The Journal of infectious diseases.

[13]  N. Breslow,et al.  Approximate inference in generalized linear mixed models , 1993 .

[14]  G. Molenberghs,et al.  Criteria for the validation of surrogate endpoints in randomized experiments. , 1998, Biometrics.

[15]  G. Batist,et al.  Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. Corfu-A Study Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Geert Molenberghs,et al.  Statistical challenges in the evaluation of surrogate endpoints in randomized trials. , 2002, Controlled clinical trials.

[17]  M J Daniels,et al.  Meta-analysis for the evaluation of potential surrogate markers. , 1997, Statistics in medicine.

[18]  H. Goldstein Nonlinear multilevel models, with an application to discrete response data , 1991 .

[19]  H. Goldstein Multilevel Statistical Models , 2006 .

[20]  Noreen Goldman,et al.  An assessment of estimation procedures for multilevel models with binary responses , 1995 .

[21]  P Flandre,et al.  Estimating the proportion of treatment effect explained by a surrogate marker. , 1999, Statistics in Medicine.

[22]  R. Wolfinger,et al.  Generalized linear mixed models a pseudo-likelihood approach , 1993 .

[23]  Harvey Goldstein,et al.  Improved Approximations for Multilevel Models with Binary Responses , 1996 .

[24]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[25]  R. Prentice Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[26]  M Buyse,et al.  Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  G. Molenberghs,et al.  Validation of surrogate end points in multiple randomized clinical trials with failure time end points , 2001 .